Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Serono Drops Diabetes Investment After Portfolio Review

This article was originally published in The Pink Sheet Daily

Executive Summary

German biopharma seeks licensing partners for diabetes treatments now in development while firm focuses R&D on cancer, other indications.

You may also be interested in...

ZymoGenetics’ Atacicept Will Enter Phase II/III For Lupus Nephritis In Q4

Company and partner Merck Serono also are working with FDA to finalize protocol for study in general systemic lupus erythematosus.

Merck Serono Phase III Trial Extension For Safinamide In Parkinson’s Misses Endpoint

Merck will pursue lower dose in future clinical trials, firm tells “The Pink Sheet” DAILY.

Merck KGaA Buys Serono, Gaining U.S. Commercial Organization

Merck acquires family-owned shares representing 64.5% of Serono's capital and will launch a tender offer for the remainder, at a total value of $13.27 bil.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts